Page 348 - Hematology_ Basic Principles and Practice ( PDFDrive )

284.e6 Part III Immunologic Basis of Hematology

235. Coppo R, Peruzzi L, Amore A, et al: Dramatic effects of eculizumab in a 238. GOV CT NCT02264639.
child with diffuse proliferative lupus nephritis resistant to conventional 239. Trials.gov C NCT00473928.
therapy. Pediatr Nephrol 30(1):167–172, 2015. 240. Fredslund F, Laursen NS, Roversi P, et al: Structure of and influence
236. Risitano A: Anti-complement treatment in paroxysmal nocturnal of a tick complement inhibitor on human complement component 5.
hemoglobinuria: where we stand and where we are going. Transl Med Nat Immunol 9(7):753–760, 2008.
UniSa 8:43–52, 2014. 241. Weston-Davies W, Nunn M, Pinto F, et al. Clinical and immunological
237. Risitano AM, Notaro R, Pascariello C, et al: The complement recep- characterisation of coversin, a novel small protein inhibitor of complement
tor 2/factor H fusion protein TT30 protects paroxysmal nocturnal C5 with potential as a therapeutic agent in PNH and other complement
hemoglobinuria erythrocytes from complement-mediated hemolysis mediated disorders. ASH Annual Meeting. 2014. Abstract 4280.
and C3 fragment. Blood 119(26):6307–6316, 2012.